Table 2.
Statistics on Endpoints of Reference Compounds Coming from: (a) the Whole Set of Relevant Publications; (b) Sets of Publications That Have Common Co-Authors (i.e. Overlap in Authors’ Names)
| (a) | ||||
|---|---|---|---|---|
| the whole set of publications | ||||
| reference drug | pEC50 Av (SD)a | pIC50 Av (SD) | pCC50 Av (SD) | Nb |
| nevirapine | 0.89 (0.9) | −0.001 (0.79) | −1.53 (0.55) | 32 |
| zidovudine | 2.07 (0.80) | N/D | −1.29 (0.66) | 36 |
| efavirenz | 2.47 (0.55) | N/D | −0.81 (0.04) | 21 |
| etravirine | 2.63 (0.21) | N/D | −0.94 (0.33) | 15 |
| (b) | |||
|---|---|---|---|
| the set of publications with common co-authors | |||
| reference drugc | pEC50a Av (SD) | pCC50 Av (SD) | Nb |
| nevirapine (1) | 0.67 (0.129) | −1.17 (0.01) | 7 |
| nevirapine (1) | 0.80 (0.35) | −1.76 (0.001) | 7 |
| nevirapine (2) | 0.67 (0.129) | −1.17 (0.01) | 7 |
| zidovudine (1) | 2.2 (0.13) | −1.55 (0.46) | 9 |
a
Average (Av) and SD value of pEC50, pIC50 and pCC50 values.
b
Number of endpoint values in the set use for the calculation of Av and SD.
c
Number of common co-authors given in parenthesis: nevirapine (1) retrieved from publications, which shared one coauthor; nevirapine (2)—from publications sharing two co-authors.